Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hanspeter Nick

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Current Opinion in Chemical Biology|July 24, 2007
Iron chelation, quo vadis?Hanspeter Nick
Experimental Hematology|June 26, 2007
Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathyMaya Otto-Duessel, Michelle Aguilar, Hanspeter Nick, et al.
Experimental Hematology|June 21, 2012
Ascorbate status modulates reticuloendothelial iron stores and response to deferasirox iron chelation in ascorbate-deficient ratsCasey Brewer, Maya Otto-Duessel, Jens Lykkesfeldt, et al.
Acta Haematologica|November 20, 2008
Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overloadMaya Otto-Duessel, Casey Brewer, Ignacio Gonzalez, et al.
Clinical Chemistry and Laboratory Medicine|February 23, 2010
Ability of deferasirox to bind iron during measurement of ironMassin Lebitasy, Els Ampe, Jean-Daniel Hecq, et al.
Current Medicinal Chemistry|April 8, 2003
Development of tridentate iron chelators: from desferrithiocin to ICL670Hanspeter Nick, Pierre Acklin, René Lattmann, et al.
European Journal of Haematology|February 5, 2009
Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemiaShahina Daar, Anil Pathare, Hanspeter Nick, et al.
Magnetic Resonance in Medicine|June 27, 2008
Influence of iron chelation on R1 and R2 calibration curves in gerbil liver and heartJohn C Wood, Michelle Aguilar, Maya Otto-Duessel, et al.
Experimental Biology and Medicine (Maywood, N.J.)|February 24, 2009
Deferasirox reduces iron overload in a murine model of juvenile hemochromatosisHanspeter Nick, Peter R Allegrini, Lucy Fozard, et al.
European Journal of Pharmacology|June 13, 2006
The new orally active iron chelator ICL670A exhibits a higher antiproliferative effect in human hepatocyte cultures than O-trensoxKarine Chantrel-Groussard, François Gaboriau, Nicole Pasdeloup, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Current Opinion in Chemical Biology|July 24, 2007
Iron chelation, quo vadis?Hanspeter Nick
Experimental Hematology|June 26, 2007
Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathyMaya Otto-Duessel, Michelle Aguilar, Hanspeter Nick, et al.
Experimental Hematology|June 21, 2012
Ascorbate status modulates reticuloendothelial iron stores and response to deferasirox iron chelation in ascorbate-deficient ratsCasey Brewer, Maya Otto-Duessel, Jens Lykkesfeldt, et al.
Acta Haematologica|November 20, 2008
Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overloadMaya Otto-Duessel, Casey Brewer, Ignacio Gonzalez, et al.
Clinical Chemistry and Laboratory Medicine|February 23, 2010
Ability of deferasirox to bind iron during measurement of ironMassin Lebitasy, Els Ampe, Jean-Daniel Hecq, et al.
Current Medicinal Chemistry|April 8, 2003
Development of tridentate iron chelators: from desferrithiocin to ICL670Hanspeter Nick, Pierre Acklin, René Lattmann, et al.
European Journal of Haematology|February 5, 2009
Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemiaShahina Daar, Anil Pathare, Hanspeter Nick, et al.
Magnetic Resonance in Medicine|June 27, 2008
Influence of iron chelation on R1 and R2 calibration curves in gerbil liver and heartJohn C Wood, Michelle Aguilar, Maya Otto-Duessel, et al.
Experimental Biology and Medicine (Maywood, N.J.)|February 24, 2009
Deferasirox reduces iron overload in a murine model of juvenile hemochromatosisHanspeter Nick, Peter R Allegrini, Lucy Fozard, et al.
European Journal of Pharmacology|June 13, 2006
The new orally active iron chelator ICL670A exhibits a higher antiproliferative effect in human hepatocyte cultures than O-trensoxKarine Chantrel-Groussard, François Gaboriau, Nicole Pasdeloup, et al.
Pageof 2